The U.S. market is anticipated to reach USD 2.30 Billion by 2035, while Europe is forecast to attain USD 2.28 Billion, supported by regulatory acceptance of in silico trials, model-informed drug development, digital twins, and virtual clinical simulation platforms.
The U.S. market is anticipated to reach USD 2.30 Billion by 2035, while Europe is forecast to attain USD 2.28 Billion, supported by regulatory acceptance of in silico trials, model-informed drug development, digital twins, and virtual clinical simulation platforms.